Media ReleasesPhylogica

View All Phylogica News

Phylogica Announces Appointment of Non-Executive Director

PERTH, Australia, 3 January 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug development and delivery platform technology, is pleased to announce the appointment of Michael Williams as Non-Executive Director.

Mr Williams is a senior pharmaceutical executive with significant global experience, most recently as Chief Operating Officer at Intarcia Therapeutics. Prior to Intarcia Therapeutics Mr Williams was Head of Global Marketing at Takeda Pharmaceuticals. Before joining Takeda, he was Vice President, Global Commercial Development for Pfizer’s Primary Care Global Business Unit. He also played a significant leadership role in Pfizer’s acquisition of King Pharmaceuticals and on alliances with Bristol Myers Squibb, Boehringer Ingelheim, Janssen and Eisai. During his time at Bristol Myers Squibb, he assumed roles of increasing responsibility notably Regional Business lead for HIV where he was responsible for the commercial performance of the HIV franchise as well as Vice President for European Marketing and Operations.

For further information please download PDF attached:
Download this document